USX: Introducing PharmaZen Limited

Pharmazen Limited Issuer Profile

PharmaZen Ltd (PAZ), trading as Waitaki Biosciences, is a a biotechnological company based in Christchurch, New Zealand.

It is principally involved in the development, manufacture and business to business marketing of specialised nutritional ingredients for human and companion animal dietary supplement products. Exported product typically generates in excess of 90% of revenune annually. 

PharmaZen offers its international customer base a portfolio of branded ingredients with specific functionality in bone and joint health, anti-inflammation, immune support, digestive health and anti-oxidant capability. 

The company is chaired by Maxwell Shepherd, with Kenneth Fergus, Wayne Burt and Peter Dobbs in directorship roles.

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

Metro Performance Glass FY26 Market Update
Devon Funds Morning Note - 13 March 2026
Devon Funds Morning Note - 12 March 2026
TCM - Financial Model
BRM - Scheme of Arrangement Update - NZ Commerce Commission
Devon Funds Morning Note - 11 March 2026
BGP - Full Year Results to 25 January 2026
BRM - Scheme of Arrangement Update - NZ Commerce Commission
The oil shock
Air New Zealand suspends FY2026 guidance